[CLSTR]
< Back to situations

[ORGANIZATION]

Mounjaro

Featured in 66 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [US] [BR] [GB]

GLP-1 drugs: clinical trends, safety, and market shifts

314 clusters · 1158 sources · last updated

Latest: GLP-1 medications and weight management strategies

The clinical and economic landscape of GLP-1 medications continues to expand. Beyond obesity, research indicates potential benefits for psychiatric, respiratory, and neurodegenerative health. Cardiovascular benefits rema

[ACTIVE] [HEALTH] [BR] [PY] [FR]

Brazil ANVISA expands product safety enforcement

43 clusters · 290 sources · last updated

Latest: Anvisa bans Accu-Chek Active glucose test strips on Amazon

Since May 2026, Brazil’s National Health Surveillance Agency (ANVISA) has intensified enforcement of sanitary rules for pharmaceuticals, cosmetics, and consumer goods. Early actions included suspending batches of statins

[ACTIVE] [HEALTH] [BR]

Brazil SUS management, regulation, and service expansion

20 clusters · 127 sources · last updated

Latest: Brazil's SUS could lose R$ 300 billion over ten years

Brazilian health officials continue to expand the Unified Health System (SUS) through digital integration, specialized care, and legislative reforms. To improve resource management, the National Health Fund launched Inve

[ACTIVE] [HEALTH] [BR] [DK]

Novo Nordisk CagriSema clinical trial results

2 clusters · 7 sources · last updated

Latest: Novo Nordisk experimental drug CagriSema shows 25% weight loss in women

Novo Nordisk has released findings from Phase 3 clinical trials regarding its experimental medication, CagriSema, which combines cagrilintide and semaglutide to treat diabetes and obesity. Initial results from the Phase

[QUIET] [HEALTH] [PT]

Medication consumption and adverse reactions in Portugal

2 clusters · 11 sources · last updated

Latest: Infarmed reports daily adverse reactions for weight loss drugs in Portugal

Data from the 2025 National Health Survey (INS 2025) indicated that 33.2% of the Portuguese population aged 15 and older consumed non-prescription medications. This usage was most prevalent in the 35 to 44 age group (40.

[QUIET] [HEALTH] [BR] [DO] [IT]

WHO childhood obesity management guidelines

3 clusters · 67 sources · last updated

Latest: WHO issues first global guidelines for childhood obesity management

The World Health Organization (WHO) has released its first global guidelines for the integrated management of obesity in children and adolescents aged 0 to 19. This follows reports that obesity prevalence in this age gro

[QUIET] [HEALTH] [US] [DE] [GB]

Eli Lilly retatrutide development and black market issues

11 clusters · 32 sources · last updated

Latest: Incretin agonists show potential in obesity treatment amid safety concerns

In early August 2026, Eli Lilly announced that its experimental obesity treatment retatrutide achieved substantial weight-loss outcomes in two phase-3 trials. Participants lost up to 22.6% of body weight over 80 weeks in

[QUIET] [HEALTH] [US] [AR] [DE]

Eli Lilly EloraTZP obesity drug clinical trials

3 clusters · 21 sources · last updated

Latest: Eli Lilly trial shows EloraTZP combination boosts weight loss

Eli Lilly has reported results from Phase 2b clinical trials for EloraTZP, a combination therapy involving eloralinantide and tirzepatide designed to treat obesity and type 2 diabetes. Data presented at the European Ass

[QUIET] [CRIME] [KR]

South Korean illegal drug and obesity medication surge

2 clusters · 7 sources · last updated

Latest: South Korea blocks 949 illegal online sales of GLP-1 obesity drugs

South Korean authorities have reported a significant rise in the illegal importation of narcotics and counterfeit obesity medications. Drug seizures at airports, particularly Incheon International Airport, have increased

[QUIET] [BUSINESS] [US]

Eli Lilly market growth and pharmaceutical expansion

4 clusters · 6 sources · last updated

Latest: Eli Lilly sees increased institutional investment and pipeline growth

Eli Lilly has experienced significant financial growth and market recognition driven by its diabetes and weight-loss medication portfolio. Analysts have issued upgrades and high price targets, with Citigroup setting a $1

[QUIET] [HEALTH] [DE] [JP] [KR]

Global Mounjaro misuse and regulation concerns

2 clusters · 8 sources · last updated

Latest: Medical Association investigates Mounjaro prescription practices in Portugal

Global concerns have emerged regarding the misuse and regulation of the diabetes and obesity medication Mounjaro. In Asia, South Korean authorities have reported a surge in counterfeit shipments, particularly from India,

Also covered in